Compass Therapeutics’ (CMPX) “Buy” Rating Reaffirmed at D. Boral Capital

Compass Therapeutics (NASDAQ:CMPX)‘s stock had its “buy” rating reaffirmed by stock analysts at D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $30.00 target price on the stock.

CMPX has been the subject of a number of other reports. Lifesci Capital initiated coverage on Compass Therapeutics in a report on Monday, October 6th. They issued an “outperform” rating and a $10.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Therapeutics in a research note on Wednesday, October 8th. Citigroup assumed coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They issued an “outperform” rating for the company. William Blair started coverage on Compass Therapeutics in a research note on Monday. They issued an “outperform” rating for the company. Finally, Cantor Fitzgerald began coverage on Compass Therapeutics in a report on Wednesday, December 3rd. They set an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Compass Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.23.

Compass Therapeutics Price Performance

Shares of NASDAQ:CMPX opened at $4.91 on Tuesday. The company has a market capitalization of $872.58 million, a P/E ratio of -10.89 and a beta of 1.45. The firm’s 50 day simple moving average is $4.91 and its two-hundred day simple moving average is $3.86. Compass Therapeutics has a 1-year low of $1.33 and a 1-year high of $5.86.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. On average, sell-side analysts anticipate that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. CIBC Bancorp USA Inc. bought a new position in Compass Therapeutics during the 3rd quarter valued at $37,000. Vivo Capital LLC grew its holdings in Compass Therapeutics by 57.9% during the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock worth $33,409,000 after acquiring an additional 3,502,000 shares during the period. Millennium Management LLC boosted its position in shares of Compass Therapeutics by 280.4% during the third quarter. Millennium Management LLC now owns 3,237,572 shares of the company’s stock worth $11,332,000 after buying an additional 2,386,367 shares during the period. Focus Partners Wealth increased its holdings in shares of Compass Therapeutics by 16.2% in the third quarter. Focus Partners Wealth now owns 15,805 shares of the company’s stock valued at $56,000 after purchasing an additional 2,206 shares during the last quarter. Finally, Citadel Advisors LLC increased its stake in Compass Therapeutics by 1,981.2% in the third quarter. Citadel Advisors LLC now owns 233,271 shares of the company’s stock valued at $816,000 after acquiring an additional 245,671 shares during the last quarter. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.